Acorda Therapeutics, Inc. (NASDAQ:ACOR) insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the completion of the transaction, the insider now owns 33,150 shares of the company’s stock, valued at $680,569.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Acorda Therapeutics, Inc. (ACOR) opened at $20.80 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. Acorda Therapeutics, Inc. has a 1 year low of $13.60 and a 1 year high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The company had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. During the same period last year, the firm posted ($0.04) EPS. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. research analysts expect that Acorda Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. State of Wisconsin Investment Board bought a new stake in Acorda Therapeutics in the 2nd quarter worth approximately $630,000. Dimensional Fund Advisors LP grew its position in shares of Acorda Therapeutics by 29.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after acquiring an additional 541,418 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Acorda Therapeutics by 306.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after acquiring an additional 403,467 shares during the period. Teachers Advisors LLC grew its position in shares of Acorda Therapeutics by 8.0% during the 2nd quarter. Teachers Advisors LLC now owns 78,886 shares of the biopharmaceutical company’s stock valued at $1,554,000 after acquiring an additional 5,837 shares during the period. Finally, State Street Corp grew its position in shares of Acorda Therapeutics by 52.4% during the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after acquiring an additional 851,290 shares during the period.

A number of equities analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price objective for the company. CIBC assumed coverage on shares of Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating for the company. Cantor Fitzgerald decreased their price objective on shares of Acorda Therapeutics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, November 15th. Leerink Swann decreased their price objective on shares of Acorda Therapeutics to $18.00 and set a “market perform” rating for the company in a report on Wednesday, November 15th. Finally, J P Morgan Chase & Co decreased their price objective on shares of Acorda Therapeutics to $19.00 and set a “neutral” rating for the company in a report on Wednesday, November 15th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Acorda Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.47.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/acorda-therapeutics-inc-acor-insider-burkhard-blank-sells-11050-shares.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.